Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

NCT03971474 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Docetaxel
DRUG: Gemcitabine
DRUG: Gemcitabine Hydrochloride
BIOLOGICAL: Pembrolizumab
DRUG: Pemetrexed
DRUG: Pemetrexed Disodium
BIOLOGICAL: Ramucirumab

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]